LABORATORY CORP OF AMERICA HOLDINGS Form 8-K June 27, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

June 27, 2018 (Date of earliest event reported)

LABORATORY CORPORATION OF
AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)1-1135313-3757370Delaware1-1135313-3757370(State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

358 South Main Street,Burlington, North Carolina27215(Address of principal executive offices)(Zip Code)(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

LabCorp® (NYSE: LH) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the UltraQual[®] Multiplex PCR Assay for HCV, HIV-1, HIV-2 and HBV for screening of donated blood plasma.

Exhibit Index Exhibit 99.1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS Registrant

By:/s/ F. SAMUEL EBERTS III F. Samuel Eberts III Chief Legal Officer and Secretary

June 27, 2018